Study design and data source
We retrospectively monitored hospitalized patients with drug recordings
from May 1, 2022, to April 30, 2023. We used muscle adverse reaction
module in ADE-ASAS-Ⅱ to extract electronic medical record (EMR). If EMR
satisfied, warning signals would be given for clinical pharmacists to
determine positive cases or not. If patients had multiple positive
signals during hospitalization, only the first signal was assessed.